People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Morphic Holding, Inc. | — | Biotechnology | Series C | $200.6M | $1.5B | 2016 |
| ShouTi Inc. | — | Biotechnology | Series D+ | $165.0M | $178.2M | 2019 |
| Schrodinger, Inc. | — | Biotechnology | Series D+ | $159.8M | $4.4B | 2010 |
| Ajax Therapeutics, Inc. | — | Biotechnology | Series C | $140.4M | $907.0M | 2019 |
| Nimbus Discovery, LLC | — | Pharmaceuticals | Seed | $5.0M | $57.1M | 2010 |
Ramy Farid at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ramy Farid on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Bruce Booth | 1 | 12 |
| Robert Weisskoff | 1 | 12 |
| David Schnell | 1 | 7 |
| Timothy Wright | 1 | 7 |
| Bruce Rogers | 1 | 7 |
| Vicki Sato | 1 | 6 |
| Michael Lynton | 1 | 6 |
| Vikas Goyal | 1 | 5 |
| Timothy A. Springer | 1 | 4 |
| Robert Farrell | 1 | 4 |
| Martin Vogelbaum | 1 | 3 |
| Daniel Auerbach | 1 | 3 |
| Timothy Springer | 1 | 3 |
| Raymond Stevens | 1 | 3 |
| CONY D'CRUZ | 1 | 2 |
| Barbara Dalton | 1 | 2 |
| Norbert Bischofberger | 1 | 2 |
| Gustav Christensen | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.